139 results about "Renal cell carcinoma" patented technology

An electrical impedance probe is provided that includes a surgical needle. In an exemplary embodiment, the probe is a two-part trocar needle designed to acquire impedance measurements at its tip. The impedance measurements are representative of the local properties of a biological substance at the needle tip. Thus, the probe may be used to confirm needle insertion into a desired anatomical target or to identify the nature of the cells surrounding the tip of the needle. In urology, this sensor is used for confirming the needle insertion into the urinary tract, for localizing renal cell carcinoma, and prostate cancer.

An IL-6 production inhibitor which comprises a hydroxamic acid derivative of formula (I)

(wherein all the symbols have the same meanings as defined in the specification), an equivalent thereof, a non-toxic salt thereof or a prodrug thereof as an active ingredient. Because of having an IL-6 production inhibitory activity, the compound of formula (I) may be useful for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia (gammophathy), Castleman's disease, intra-atrial myxoma, diabetes, autoimmune disease, hepatitis, colitis, graft-versus-host disease, infectious diseases, endometriosis and solid cancer.

The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity of CA IX, in particular, tumors such as colorectal cancer, renal cell carcinoma (RCC), cervical and other cancers of epithelial origin.

It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.

This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.

The present invention relates to a method for the prognosis of bone metastasis in renal cell carcinoma which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering renal cell carcinoma. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of renal cell carcinoma metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering renal cell carcinoma and for classifying a subject from renal cell carcinoma into a cohort.

The present invention relates to tumor markers useful for screening, diagnosing, predicting and identifying subtypes of renal cell carcinoma. The invention also relates to the use of the identified antigenic proteins in immunoassays and the use of tumor markers as immunogens to stimulate an immune response. The present invention also relates to the use of the tumor marker in the preparation of antibodies and antibody fusion proteins against tumor markers.

Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cancer. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cancer is esophageal cancer, hepatocellular carcinoma, colon cancer, prostate cancer, lung cancer, gastric carcinoma, renal cell carcinoma, bone cancer, breast cancer, cervical cancer, brain cancer, or a cancer associated with the tumor suppressor gene p53.

Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.

The invention discloses an application of salinomycin in the preparation of medicaments for resisting various human malignant tumors. Salinomycin adopted by the present invention assists in inhibiting the growth of a plurality of human tumor cells and metastatic tumor cells. Further, salinomycin is capable of killing a plurality of tumour stem cells such as lung cancer stem cells. Salinomycin haspotentials to be adopted in the exploitation of anticancer medicaments aimed at tumour stem cells, and has important values in the exploitation of medicaments for resisting various human malignant tumors such as lung cancers, skin cancers, pancreas cancers, colon cancers, liver cancers, rectal cancers, brain cancers, renal cell carcinoma, brain-metastatic prostate cancers, and the like.

Objective methods for detecting and diagnosing renal cell carcinoma (RCC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of RCC-associated gene that discriminates between RCC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of renal cell carcinoma, methods of treating renal cell carcinoma and method of vaccinating a subject against renal cell carcinoma.

The invention discloses a completely humanized anti-VEGFR-2 monoclonal antibody, and discloses a method of screening by adopting a phage antibody library technique and preparing the novel anti-VEGFR-2 monoclonal antibody or a segment thereof by utilizing a genetic engineering manner. The antibody can be a univalent antibody or a bivalent antibody. The antibody can interdict VEGF-A, VEGF-C, VEGF-D and VEGF-E simultaneously so that the antibody has more effective anti-angiogenesis effects. The antibody can be applied for treating diseases caused by tumor angiogenesis. The diseases comprise, but not limited to, gastric cancer, adenocarcinoma of esophagogastric junction, non-small cell lung cancer, metastatic non-small cell lung cancer, hepatocellular carcinoma, metastatic hepatocellular carcinoma, HER2-negtive metastatic breast cancer, metastatic colorectal cancer, metastatic melanoma, metastatic renal cell carcinoma, glioblastoma, ovarian cancer, prostate cancer and solid tumor.

The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

The invention relates to clinical application of a substituted aryl hydrazone compound and a derivative thereof serving as an anti-tumor necrosis factor inhibitor. A test result shows that the compound has a lower cytotoxicity in animal bodies, so the medical compound is expected to be used as an anti-TNF-alpha and TNF-beta inhibitor in the clinical application and is mainly used for treating some TNF related immunological diseases such as rheumatic arthritis, inflammatory bowel diseases, diabetes, hematosepsis, psoriasis, ankylosing spondylitis and some communicable diseases including HIV. A current TNF related research also shows that the medical compound can be used for treating clinical blood and solid tumor such as myelodysplastic syndrome, myelofibrosis, acute bone marrow cell leucocythemia, acute/chronic graft-versus-host reaction, ovarian cancer, nephrocyte cancer and the like.

The present invention relates to methods for treating at least one renal cell carcinoma related condition or pathology, including therapeutic compositions, methods and devices, using TNF antagonists.

The invention discloses an application of CD73 as a stem cell surface marker of renal clear cell carcinoma. The application is that a substance for detecting CD73 can be used for preparing the following products: 1) a product for detecting or screening the stem cells of renal clear cell carcinoma; 2) a product for diagnosis or auxiliary diagnosis of renal clear cell carcinoma; 3) a product for diagnosis or auxiliary diagnosis of the malignancy degree of renal clear cell carcinoma of a patient to be detected; and 4) a product for treating renal clear cell carcinoma by taking CD73 as a target. In-vitro experiments and animal experiments prove that the CD73 can be used as a surface marker of the stem cells of renal clear cell carcinoma; and the result of clinical sample analysis indicates that the proportion of CD73 positive cells is closely related to the clinical classification of renal clear cell carcinoma. The invention provides a new molecular target CD73 to the identification of the stem cells of renal clear cell carcinoma as well as the diagnosis, classification and detection of renal clear cell carcinoma, and provides a simple and efficient method for the prognosis of renal clear cell carcinoma.

The present invention provides novel compounds of the formula (I) and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

The invention discloses a biomarker and a method for predicating relapse and mortality risk of renal cell carcinoma, and belongs to the renal cell monitoring technology. The biomarker is used for predicating the relapse or mortality risk of a patient with renal cell carcinoma after tumor is resected. The biomarker is one of the following characteristic genomes: Sig2.5, Sig0.83, Sig0.83sub1, Sig0.83sub2 and Sigcmbn; the relapse or mortality risk of the patient with renal cell carcinoma can be predicated by detecting the expression condition of the characteristic genomes in the biomarker. The biomarker has the advantages of being capable of effectively estimating the relapse or mortality risk of the patient with renal cell carcinoma after tumor is resected, so that the patient management canbe greatly performed; and novel assistant treatment or targeted treatment can be specifically performed on some patients with high relapse or mortality risk.

The invention discloses a novel fusion gene for MiT familial translocation renal cell carcinoma and a detection primer and application of the novel fusion gene. The gene is a PRCC-MITF fusion gene, and is formed by fusing a PRCC exon 5 and an MITF exon 4. A PCR primer for detecting PRCC-MITF translocation tumors comprises an upstream primer as shown in SEQ ID NO. 1 and a downstream primer as shown in SEQ ID NO. 2. The specific PCR primer is designed for the novel fusion gene discovered by high-throughput sequencing, the detection range of the original detection means is expanded, the novel fusion gene is applied to clinical application, and the detection ratio and accuracy rate of the MiT familial translocation renal cell carcinoma can be improved. The novel fusion gene provides a basis for diagnostic typing and molecular targeting treatment.

The invention discloses a cancer subtyping method and a device based on RNA targeted sequencing and machine learning. According to the method, through RNA targeted sequencing technology, a target genearea is concentrated efficiently. Through steps of inverse transcription, database establishing and sequencing, second-generation sequencing data of the target area are obtained. Furthermore a randomforest algorithm is used for training on a TCGA dataset for obtaining a tumor typing predicting model, thereby accurately performing cancer subtyping. The method according to the invention can obtaina model for realizing lung cancer and renal cell carcinoma typing with high accuracy. The method according to the invention can reduce typing cost. Furthermore the typing speed, precision and the typing result accuracy are better than that of a traditional method.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect expression levels of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma.